Will pharma finally score a policy win for 340B?
PharmaVoice
JUNE 16, 2025
The 340B Drug Pricing Program has long been a contentious issue for pharma. The American Hospital Association has pushed back on claims the program isn’t working as intended, saying it provides a needed buffer for patients in the face of rising drug prices. Please let us know if you have feedback.
Let's personalize your content